Thu.Apr 18, 2024

article thumbnail

Novo Nordisk attracts lawmakers' scrutiny after dropping discounted insulin product Levemir

Fierce Pharma

Novo Nordisk is receiving pushback from a trio of lawmakers over its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year | Novo Nordisk is receiving pushback from a trio of lawmakers on its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year.

199
199
article thumbnail

23andMe: What If …

MedCity News

A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision? The post 23andMe: What If … appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AbbVie touts Rinvoq win in giant cell arteritis, potentially teeing up another label expansion

Fierce Pharma

Less than a year ago, AbbVie's star immunology drug Rinvoq picked up its seventh FDA approval< | AbbVie's Rinvoq has racked up seven FDA approvals in recent years, and another expansion into giant cell arteritis could be in the cards after a positive trial.

FDA 199
article thumbnail

Heart disease risk ‘calculator’ could save lives

pharmaphorum

UK researchers describe an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the next 10 years.

75
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Sanofi, busy with cost-savings campaign, restructures US commercial vaccine group

Fierce Pharma

During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group. | During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group. A spokesperson said the company would offer affected employees a chance to apply for new roles, plus "outplacement services.

152
152
article thumbnail

Outrun Therapeutics announces launch with $10m seed funding

Pharmaceutical Technology

Outrun Therapeutics announced its launch with $10m seed funding to advance a protein stabilisation pipeline focused on E3 ligase inhibitors.

85

More Trending

article thumbnail

Clearmind licenses psychedelic compounds for mental disorders

Pharmaceutical Technology

Clearmind Medicine has entered into a licensing agreement with Yissum to develop Generation 3.0 psychedelic compounds for mental disorders.

article thumbnail

Amgen CEO nabs pay raise thanks to Horizon deal. Does that incentivize aggressive M&A?

Fierce Pharma

Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company’s acquisition of Horizon Therapeutics. | Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company's acquisition of Horizon Therapeutics.

147
147
article thumbnail

In the World of Interoperability, How to Meaningfully Strengthen Cybersecurity

MedCity News

Achieving strong cybersecurity is a vast, interconnected web that must incorporate the correct software, procedures, and workflows and take into account the human element across an entire organization. The post In the World of Interoperability, How to Meaningfully Strengthen Cybersecurity appeared first on MedCity News.

68
article thumbnail

After coming up short in COVID, Valneva focuses on chikungunya vaccine launch

Fierce Pharma

After striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is taking its swings at what it does best—developing, manufacturing and commercializing vaccines for a variety o | After striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is back to doing what it does best—developing, manufacturing and commercializing vaccines for a variety of infectious diseases with unmet needs.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Included Health Announces New Specialty Care Offering

MedCity News

Included Health’s new specialty care clinic, which will become available in 2025, is starting by offering three centers: the Cancer Center, the Center for Women’s Health and the Center for Metabolic Health. The post Included Health Announces New Specialty Care Offering appeared first on MedCity News.

64
article thumbnail

Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platform

Fierce Pharma

History is coming full circle as induced pluripotent stem (iPS) cell-derived cell therapy maker Shinobi Therapeutics links up with Panasonic and Japan’s Kyoto University, where the first mouse iPS | Shinobi Therapeutics has entered an accord with electronics powerhouse Panasonic and Kyoto University in a bid to develop a new closed-system manufacturing device for cheaper and more efficient production of cell therapies.

article thumbnail

Novel Parkinson’s Disease Drug Will Join AbbVie With Positive Phase 3 Data In Hand

MedCity News

Cerevel Therapeutics drug tavapadon met the main and secondary goals of a pivotal Parkinson’s disease clinical trial. That drug and others will join the neuroscience portfolio of AbbVie, which is in the process of acquiring Cerevel. The post Novel Parkinson’s Disease Drug Will Join AbbVie With Positive Phase 3 Data In Hand appeared first on MedCity News.

article thumbnail

Monitoring pharmaceuticals in the environment

European Pharmaceutical Review

What are the three main challenges of monitoring pharmaceuticals in the environment? Andreas Häner (AH): Roche, along with other pharmaceutical companies, acknowledges concerns about pharmaceuticals in the environment (PiE). While pharmaceutical manufacturing’s overall contribution is small compared to patient use and inappropriate disposal of pharmaceuticals, inadequately managed manufacturing emissions can impact local environments and receiving waters.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Medicare’s Push To Improve Chronic Care Attracts Businesses, but Not Many Doctors

MedCity News

Medicare’s Chronic Care Management program reduced emergency room and in-patient hospital visits and lowered total health spending, but uptake has been sluggish for a variety of reasons. The post Medicare’s Push To Improve Chronic Care Attracts Businesses, but Not Many Doctors appeared first on MedCity News.

Doctors 60
article thumbnail

Ireland sets out its stall as Europe’s medtech hotspot

pharmaphorum

Ireland makes the case for its role as Europe's medtech hotspot, helping companies tackle emerging challenges like digitalisation and sustainability.

58
article thumbnail

Hospital M&A Activity in 2024: What to Expect

MedCity News

Q1 2024 saw a significant rise in the number of hospital M&A deals compared to the past three Q1s. Experts believe this M&A activity will continue to climb throughout this year and next — motivated by both financial distress and hospitals’ desire to improve strategic business lines like value-based care and digital healthcare services. The post Hospital M&A Activity in 2024: What to Expect appeared first on MedCity News.

article thumbnail

Coya Therapeutics CEO Discusses Recent Data Discovery from a Study of Coya 302, a Potential Treatment for ALS

PharmExec

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides an update on the progress of Coya 302 as a treatment for ALS.

52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Healthcare Docket: Help Wanted — Doctor Expert Witnesses

MedCity News

Major malpractice verdicts have spiked in recent years. The post Healthcare Docket: Help Wanted — Doctor Expert Witnesses appeared first on MedCity News.

Doctors 57
article thumbnail

Inflammation among current dementia research focus, says Alchemab CSO

Pharmaceutical Technology

Inflammation, cell metabolism and neuronal health are current key areas of focus for dementia researchers, according to Jane Osbourn, chief scientific officer (CSO) at Alchemab.

52
article thumbnail

Single-Use Technologies Reinforce Fluid-Handling Workflows (INTERPHEX 2024)

PharmaTech

Pharmaceutical Technology® spoke with Nicole Hunter, Watson-Marlow Fluid Technology Solutions’ head of Global WMArchitect, about the impact single-use technologies have on fluid-handling workflows in bioprocessing.

article thumbnail

Antibiotic demonstrates non-inferiority to a leading gonorrhoea treatment

European Pharmaceutical Review

New trial results for GSK’s oral gepotidacin, a potential first-in-class oral antibiotic, has shown that it was non-inferior with 92.6 percent success rates in patients with uncomplicated urogenital gonorrhoea (GC). “These results highlight the potential of gepotidacin as a new oral treatment option given the rising incidence of gonorrhoea worldwide” In the pivotal EAGLE-1 Phase III trial, comparatively, intramuscular ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy, a

Leads 52
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

Levo Health Sponsors Tampa Bay Wave’s HealthTech|X Accelerator Program

LEVO Health

At Levo Health, we’re always on the lookout for opportunities to push the boundaries of healthcare marketing and support innovations that can transform the industry. This year, we’re thrilled to take our commitment a step further by sponsoring the 2024 HealthTech|X Accelerator program hosted by Tampa Bay Wave. Tampa Bay Wave has a proven track record of fostering startup success, having supported 527 startups, collectively raising over $900 million in capital and creating more than 5

article thumbnail

A Work in Progress: CCC and Artificial Intelligence

Copyright Clearance Center

In a recent town hall webinar, The Heart of the Matter: Copy­right, AI Training and LLMs, CCC (Copyright Clearance Center) made the case that current artificial intelligence (AI) technology infringes copyrights, both in the way its underlying large language models (LLMs) are developed, or trained, and in the outputs it enables users to create.

article thumbnail

Aligos Therapeutics gets grant for treatment of disease using compounds of formula i

Pharmaceutical Technology

Discover the groundbreaking patent granted to Aligos Therapeutics Inc for compounds of Formula I, paving the way for innovative treatments and pharmaceutical compositions. Explore the potential of these compounds for treating diseases.

article thumbnail

Novo Nordisk Foundation's SVP of Natural & Technical Sciences Discusses the Future of Quantum Sensing in Clinical Research

PharmExec

In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation, offers her thoughts on where quantum sensing is heading when it comes to aiding treatment development and clinical studies.

52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Huadong Medicine gets grant for multi-domain active protein for treating metabolic diseases

Pharmaceutical Technology

Discover the groundbreaking multi-domain active protein patented by Huadong Medicine Co Ltd for treating metabolic diseases. With increased efficacy and simplified preparation process, this protein is set to revolutionize existing treatments.

article thumbnail

Meet Our Mentor: Matt Penn

MedTechVets

MAR 18th – We were proud to interview MedTechVet Academy Mentor, Matt Penn. Matt is currently the North America Account Manager for Vernay. Simply put, the more one transitions the more one grows & having a valuable mentor & support system can at times make all the difference in succeeding. What led you to obtain a role within the MedTech space?

Medical 52
article thumbnail

Foghorn Therapeutics gets grant for compounds for treating BAF complex-related disorders

Pharmaceutical Technology

Discover the groundbreaking patent granted to Foghorn Therapeutics Inc for compounds targeting BAF complex-related disorders. Learn about the specific structure outlined in the claim and its potential in medical treatments.

Medical 52
article thumbnail

Improving ADC Manufacture Means Stricter Containment Requirements and Continuous Advancement of Analytics (INTERPHEX 2024)

PharmaTech

The improvement of ADC manufacturing now demands increased containment requirements and continually advancing analytical detection of molecules in manufacturing spaces.

article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.